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Background: Therapeutic benefits of peptide-based drugs is limited by rapid renal elimination. 
Methods: Therefore, to prolong the biological action profile of the recently characterised triple-acting hybrid peptide, exendin-4/gastrin/xenin-8-Gln, a fatty-acid (C-16) has been covalently attached, creating exendin-4(Lys27PAL)/gastrin/xenin-8-Gln. Exendin-4/gastrin and liraglutide/gastrin/xenin-8-Gln were also synthesised as direct comparator peptides. 
Results: All hybrid peptides evoked significant concentration-dependent increases of insulin secretion from isolated murine islets and BRIN-BD11 cells. Following administration of peptides with glucose to mice, all hybrids significantly reduced the overall glycaemic excursion and increased insulin concentrations. In contrast to other treatments, exendin-4(Lys27PAL)/gastrin/xenin-8-Gln displayed impressive anti-hyperglycaemic actions even 12 h after administration, highlighting protracted duration of effects. Exendin-4/gastrin/xenin-8-Gln. exendin-4/gastrin, and exendin-4(Lys27PAL)/gastrin/xenin-8-Gln were then progressed to a 31-day twice-daily treatment regimen in obese-diabetic ob/ob mice. All treatments decreased non-fasting glucose and HbA1c concentrations, as well as enhancing circulating and pancreatic insulin levels. Exendin-4/gastrin and exendin-4/gastrin/xenin-8-Gln also decreased food intake. Glucose tolerance was improved by all treatments, but only exendin-4(Lys27PAL)/gastrin/xenin-8-Gln augmented glucose-induced insulin secretion. Interestingly, treatment regimens that included a xenin component induced clear advantages on the metabolic response to GIP and the glucose-lowering actions of insulin. 
Conclusion: This study emphasises the therapeutic promise of long-acting, multi-targeting hybrid gut peptides for type 2 diabetes. 
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Introduction
The anti-diabetic advantages of bariatric surgery are credited to alterations in the release profile and biological activity of a range of regulatory gastrointestinal (GIT) peptide hormones [1]. As a result, combining therapeutically viable GIT peptides, and more recently, using single hybrid peptides capable of concurrent activation of various GIT hormone receptors, is receiving increasing interest as a new approach for type 2 diabetes mellitus (T2DM) treatment [2-8]. Many of these hybrid peptides integrate a glucagon-like peptide-1 (GLP-1) structural spine [9-12]. This is because GLP-1 receptor activation induces numerous well-characterised anti-diabetic benefits [13], and the fact that GLP-1 mimetics are clinically approved [14]. Dual-acting [2,4,15], and more recently triple-acting [6,7,16] hybrid peptides have been described. In this regard, our laboratory has recently documented the metabolic benefits of a novel triple-acting GLP-1/gastrin/xenin hybrid peptide, namely exendin-4/gastrin/xenin-8-Gln [12]. Exendin-4/gastrin/xenin-8-Gln was able to activate GLP-1, gastrin and xenin cell signalling pathways and exerted clear anti-diabetic actions in high-fat-fed mice [12]. This was established to be linked to a combination of the benefits and differing mechanisms of action of exendin-4 [17], gastrin [18] and xenin [19] in T2DM. 
Whilst exendin-4/gastrin/xenin-8-Gln displays clear therapeutic promise, it is nonetheless vulnerable to efficient renal filtration. One approach to circumvent this, is through covalent attachment to a fatty-acid adduct [20]. Indeed, this is exemplified by liraglutide, the clinically approved T2DM drug that has a C-16 fatty-acid molecule attached to Lys26, enabling non-covalent self-association with albumin [20,21]. For liraglutide, acylation does result in slightly lower intrinsic in vivo bioactivity [22], but this is more than compensated for by a significant extension to the circulating half-life [23]. In accord with this, acylation has been employed to generate many long-acting peptide analogues, including but not limited to, apelin [24], insulin [25], GIP [26-29] and xenin [30,31].




Test peptides (Table 1) were acquired from EZBiolab Inc. (Westfield, IN, USA) and characterisation confirmed by in-house RP-HPLC and MALDI-TOF MS testing, as described previously [29]. Table 1 presents the structures of peptides utilised for this study. The full sequence of exendin-4(Lys27PAL)/gastrin/xenin-8-Gln comprises the first N-terminal 28 amino acid residues of exendin-4 with C-18 acylation at Lys27, followed by gastrin-6, and then xenin-8-Gln, with each peptide element individually reported to retain full biological activities of the respective parent peptides [15,35]. Importantly, exendin-4/gastrin/xenin-8-Gln has recently been shown to possess triple receptor activation functionality [12] and acylation of exendin-4 at Lys27 does not impair biological efficacy [34].

In vitro and ex vivo insulin secretory studies
As described previously [12,36], acute effects of test peptides on insulin secretion was examined in clonal pancreatic BRIN-BD11 beta-cells and collagenase-isolated mouse (NIH Swiss mice, 14 week-old) islets using 20 and 60 min incubation periods, respectively, with insulin concentrations measured by RIA [37].

Animals
Studies were conducted in lean male NIH Swiss mice (12-14 weeks old, Envigo Ltd, UK, n=8) or C57BL/6J male obese diabetic ob/ob mice (12 weeks, Envigo Ltd, UK, n=8), as appropriate. All mice were housed individually with free access to drinking water and standard laboratory chow (10% fat, 30% protein and 60% carbohydrate, Trouw Nutrition, UK). Animal experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and approved by the University of Ulster Animal Welfare and Ethical Review Body (AWERB).

Acute and persistent in vivo studies
Fasted (18 h) lean mice were used to assess acute effects of peptides on glucose-lowering and insulin secretory responses. Mice received an injection of glucose (18 mmol/kg bw, intraperitoneal (i.p.)) alone or in combination with test peptides (each at 25 nmol/kg bw, i.p.). This dose was selected based on previous studies with exendin-4/gastrin/xenin-8-Gln [12]. Glucose and insulin concentrations were measured at time points indicated in Figure 2A,B. For persistent glucose-lowering effects, saline vehicle (0.9% (w/v), NaCl, i.p.) or peptides (25 nmol/kg bw, i.p.) were injected 8 or 12 h before administration of a glucose challenge (18 mmol/kg bw; i.p.) in mice, and glucose levels assessed at time points indicated in Figure 2C,D.
 
Sub-chronic in vivo studies
The ob/ob mice received twice-daily (09:30 and 17:00 h) injections of saline (0.9% NaCl, i.p.), exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln or exendin-4(Lys27PAL)/gastrin/xenin-8-Gln (each at 25 nmol/kg bw, i.p.) for a period of 31 days. Circulating glucose and insulin, as well as food intake and body weight, were monitored at regular intervals. Plasma glucagon, amylase activity, 24-h glucose profile and whole blood HbA1c were measured on day 31. At the end of the treatment period, glucose tolerance (18 mmol/kg bw; i.p.), metabolic response to GIP (18 mmol/kg glucose in combination with native GIP (25 nmol/kg); i.p.) and insulin sensitivity (50 U/kg bw; i.p.) tests were conducted. Percentage body fat and pancreatic insulin content were also determined [12].

Biochemical analysis 
All standard biochemical analyses and blood withdrawal from mice were conducted as previously described36. HbA1c, plasma glucagon and amylase activity were measured using commercial kits, namely A1cNow+ (PTS diagnostics, IN, USA), EZGLU-30K ELISA (Merck Millipore, Germany) and colorimetric (ab102523, Abcam, Cambridge, UK) respectively. 

Statistical analysis 
All statistical analyses were performed using GraphPad PRISM (Version 5). Results are expressed as means±S.E.M. and data compared using repeated measures ANOVA followed by the Student-Newman-Keuls post hoc test. Groups of data were considered significantly different if p < 0.05.

Results
In vitro and ex-vivo insulin secretion 
All peptides stimulated (p < 0.05 to p < 0.001) concentration-dependent insulin secretion from BRIN-BD11 cells at both basal and elevated glucose levels (Figure 1A,B). Exendin-4/gastrin/xenin-8-Gln increased (p < 0.05 to p < 0.001) insulin secretion at all peptide concentrations (10-12 – 10-6 mol/l) examined (Figure 1B). Insulinotropic actions (p < 0.05 to p < 0.001) of all peptides (10-6 mol/l) were also apparent in isolated murine islets (Figure 1C). However, only exendin-4/gastrin and exendin-4/gastrin/xenin-8-Gln induced significant (p < 0.001) insulin secretion from islets at a concentration of 10-8 M (Figure 1C).

Acute and persistent in vivo effects 
Following an i.p. glucose challenge, exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln, exendin-4(Lys27PAL)/gastrin/xenin-8-Gln and liraglutide/gastrin/xenin-8-Gln significantly (p < 0.05 to p < 0.001) decreased individual and 0-60 min overall AUC glucose when compared to glucose alone injection (Figure 2A). As might be expected, corresponding glucose-stimulated insulin secretion (GSIS) was elevated (p < 0.05 to p < 0.001) by all treatments (Figure 2B). Administration of exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln or exendin-4(Lys27PAL)/gastrin/xenin-8-Gln 8 hours prior to the glucose load resulted in decreased (p < 0.05 to p < 0.001) overall and individual glycaemic levels compared to saline vehicle controls (Figure 2C). Interestingly, although liraglutide/gastrin/xenin-8-Gln reduced (p < 0.05) glucose levels at 60 min post-injection, the overall glycaemic excursion, as depicted by AUC values, was not different from controls (Figure 2C). When peptides were administered 12 hours previous to an i.p. glucose challenge, only exendin-4(Lys27PAL)/gastrin/xenin-8-Gln reduced (p < 0.01) overall AUC glucose values (Figure 2D). 

Effects of twice-daily administration of exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln and exendin-4(Lys27PAL)/gastrin/xenin-8-Gln on metabolic indices in ob/ob mice 
The ob/ob mice presented with increased (p < 0.05 to p < 0.001) body weight, percentage fat mass and food intake form the outset of the study (Figure 3A,B). Twice-daily administration of exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln and exendin-4(Lys27PAL)/gastrin/xenin-8-Gln for 31 days had no effect on body weight or fat mass (Figure 3A). However, both exendin-4/gastrin and exendin-4/gastrin/xenin-8-Gln significantly reduced (p < 0.05 and p < 0.01) food intake from day 3 onwards (Figure 3B), and all treatment regimens reduced (p < 0.05 to p < 0.001) circulating glycaemic levels from day 6 forwards (Figure 3C). In keeping with reduced blood glucose concentrations, HbA1c concentrations were substantially (p < 0.05 to p < 0.01) reduced by all interventions in ob/ob mice, and not different from lean controls (Figure 3D). In agreement, a 24 h glucose profile demonstrated all treatment groups to have reduced (p < 0.05 to p < 0.001) glucose levels at many of the observation time-points (Figure 3E). Circulating plasma insulin concentrations were significantly (p < 0.05 to p < 0.001) elevated in all ob/ob treatment groups when compared to control mice (Figure 3F).  

Effects of twice-daily administration of exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln and exendin-4(Lys27PAL)/gastrin/xenin-8-Gln on glucose tolerance and GIP sensitivity in ob/ob mice
Exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln and exendin-4(Lys27PAL)/gastrin/xenin-8-Gln treatment resulted in improved 0-60 min AUC glucose values following an i.p. glucose challenge (Figure 4A). Individual glucose levels were only decreased (p < 0.01) by exendin-4/gastrin/xenin-8-Gln (Figure 4A). GSIS was elevated by all treatment regimens, but only exendin-4(Lys27PAL)/gastrin/xenin-8-Gln significantly (p < 0.05) augmented AUC insulin values (Figure 4B). Interestingly, all treatment regimens that incorporated a xenin element, namely exendin-4/gastrin/xenin-8-Gln and exendin-4(Lys27PAL)/gastrin/xenin-8-Gln, improved (p < 0.01 and p < 0.05, respectively) the biological actions of GIP (Figure 4C,D). 

Effects of twice-daily administration of exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln and exendin-4(Lys27PAL)/gastrin/xenin-8-Gln on insulin sensitivity, pancreatic insulin content, plasma glucagon and amylase activity in ob/ob mice 
Exendin-4/gastrin/xenin-8-Gln and exendin-4(Lys27PAL)/gastrin/xenin-8-Gln treatment significantly (p < 0.05 and p < 0.001) improved the ability of exogenously delivered insulin to reduce blood glucose levels when compared to saline treated ob/ob controls (Figure 5A,B). Exendin-4/gastrin did not affect the glucose-lowering actions of insulin (Figure 5A,B). Total pancreatic insulin was increased (p < 0.05 and p < 0.01) in all treatment groups (Figure 5C). Circulating plasma glucagon levels and amylase activity were not altered by any of the treatments (Figure 5D,E). However, glucagon levels were elevated (p < 0.001) in all ob/ob mice compared to lean control mice (Figure 5D).  

Discussion
In the current study, the recently described triple-acting peptide, exendin-4/gastrin/xenin-8-Gln [12], was conjugated to a C-16 palmitic acid moiety at Lys27 in a bid to prolong duration of biological action. In addition, the biological efficacy of a second novel acylated hybrid peptide, namely liraglutide/gastrin/xenin-8-Gln, was also determined and directly compared alongside exendin-4(Lys27PAL)/gastrin/xenin-8-Gln. 
           Exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln and liraglutide/gastrin/xenin-8-Gln stimulated insulin secretion from BRIN-BD11 beta-cells and mouse islets at physiological and, more prominently, elevated glucose concentrations in a concentration-dependent manner [12]. It is clear that the non-acylated triple-acting hybrid peptide possessed increased bioactivity when compared to exendin-4/gastrin, suggesting beneficial additive efficacy of each component of the hybrid. Importantly, exendin-4(Lys27PAL)/gastrin/xenin-8-Gln and liraglutide/gastrin/xenin-8-Gln displayed similar insulin-releasing properties as exendin-4/gastrin/xenin-8-Gln, confirming that fatty-acid derivation did not hinder biological activity [32,38]. Both fatty-acid derivatised peptides, exendin-4(Lys27PAL)/gastrin/xenin-8-Gln and liraglutide/gastrin/xenin-8-Gln, appeared to have somewhat reduced insulinotropic potency when compared to non-acylated comparators. This effect was also observed during acute in vivo studies, and is likely to be linked to protein binding and decreased immediate availability of ‘free’ peptide to bind and activate receptors [27]. Nonetheless, overall improvement of in vivo pharmacokinetics would be expected to offset any reduced intrinsic bioactivity. Indeed, all peptides still enhanced glycaemic control and insulin secretion in normal mice. This further corroborates that acylation at Lys27 in exendin-4 at does not negatively affect receptor binding and modulation of intracellular pathways leading to insulin release [34]. 
	The persistent glucose-lowering action of exendin-4(Lys27PAL)/gastrin/xenin-8-Gln was evident even 12 hours after administration in mice, whereas exendin-4/gastrin/xenin-8-Gln was active for only around 8 hours. Interestingly, liraglutide/gastrin/xenin-8-Gln did not appear to have a protracted pharmacodynamics profile, which does somewhat contrast with previous studies using liraglutide [14,23,39]. Reduced efficacy of liraglutide/gastrin/xenin-8-Gln could be related to peptide dose or mouse model employed, although further studies are required here. Furthermore, stearic hindrance issues may also be involved with liraglutide/gastrin/xenin-8-Gln, although the peptide did display good in vitro and acute in vivo biological activities. Ultimately, development of specific bioassays to determine plasma peptide kinetics would be required, but this is far beyond the extent of our present investigation. In addition, the degree of albumin binding of both fatty-acid dervatised peptides may also be interesting to quantify [40,41]. However, based on the positive acute in vivo findings, exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln and exendin-4(Lys27PAL)/gastrin/xenin-8-Gln were progressed to a 31-day twice-daily injection regimen in ob/ob mice, to examine anti-diabetic efficacy. 
          Leptin deficient ob/ob mice on the C57BL/6J background present with insulin resistance, elevated circulating glucose, insulin and lipids as well as excessive weight gain [42]. Thus, C57BL/6J ob/ob mice represent an excellent challenge for evaluation of current and experimental anti-diabetic drugs [43]. Remarkably, 31 days twice-daily injection of exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln or exendin-4(Lys27PAL)/gastrin/xenin-8-Gln improved glycaemic control, glucose tolerance, elevated plasma and pancreatic insulin as well as reducing HbA1c concentrations. Observed benefits are consistent with our previous study utilising exendin-4/gastrin/xenin-8-Gln in high-fat-fed mice [12], and presumably linked to the actions of GLP-1, gastrin and xenin as promoters of beta cell function and survival [44-46]. Further to this, amylase activity, a biochemical marker for acute pancreatitis [47], was unaltered, confirming safety of these treatment approaches. Unlike the other treatment interventions, exendin-4(Lys27PAL)/gastrin/xenin-8-Gln did not exert appetite suppressive actions, and this could be related to alterations in non-albumin bound ‘free’ peptide levels. Since body weights of ob/ob mice were unaltered, despite elevated circulating insulin in all treated mice, a potential change in metabolic rate may have occurred in treatment groups where food intake was reduced. However, glucagon levels were unaltered in all ob/ob mice, but this could be linked to a combination of the ability of GLP-1 to impede [48], whereas xenin and gastrin to stimulate [49,50], secretion of glucagon.
	It could be hypothesised that a key benefit of exendin-4(Lys27PAL)/gastrin/xenin-8-Gln over the other treatment modalities employed would be linked to a prolonged biological half-life. However, obvious benefits of exendin-4(Lys27PAL)/gastrin/xenin-8-Gln over exendin-4/gastrin/xenin-8-Gln were not conspicuous, barring a possible augmentation of GSIS following an intraperitoneal glucose load. This could relate to the dosing regimen employed (twice-daily), and use of a more extended period between drug administrations, as employed for other long-acting regulatory gut peptide analogues (one injection every 3 days) [51], may have better differentiated between therapeutic efficacy. More interestingly, both hybrids that included a xenin element, exendin-4/gastrin/xenin-8-Gln and exendin-4(Lys27PAL)/gastrin/xenin-8-Gln, but not exendin-4/gastrin, substantially potentiated the biological actions of GIP. Thus, GIP activity is known to be compromised in T2DM [17] and is believed to represent a pathophysiological characteristic of the disease [52]. Since xenin is recognised to augment the biological actions of GIP [30,31,53], this could be a major contributor to the observed benefits. Notably, insulin sensitivity was also improved in these two specific treatment groups of ob/ob mice, implying that xenin-containing hybrids may not only augment beta-cell function, but also enhance peripheral insulin action [12]. 
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Figure 1. Influence of exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln, exendin-4(Lys27PAL)/gastrin/xenin-8-Gln and liraglutide/gastrin/xenin-8-Gln on insulin secretion. (A,B) BRIN-BD11 cells were incubated with peptides (10-12 to 10-6 mol/l; 20 min) in presence of (A) 5.6 or (B) 16.7 mmol/l glucose. (C) Isolated mouse islets were incubated with peptides (10-8 to 10-6 mol/l; 60 min) at 16.7 mmol/l glucose. Values represent mean±S.E.M. (A,B, n=8 and C, n=4). *p < 0.05, **p < 0.01 and ***p < 0.001 compared to appropriate glucose control. 

Figure 2. Influence of exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln, exendin-4(Lys27PAL)/gastrin/xenin-8-Gln and liraglutide/gastrin/xenin-8-Gln on glucose and insulin responses in lean mice.  (A,B) Acute effects of peptides on (A) blood glucose and (B) plasma insulin were measured before and after injection (i.p.) of glucose (18 mmol/kg) or glucose in combination with peptides (each at 25 nmol/kg) in 18 h fasted mice. (C,D) Blood glucose was measured following a glucose challenge (18 mmol/kg; i.p.) in 18 h fasted mice intraperitoneally injected (C) 8 or (D) 12 h previously with saline (0.9 % NaCl), exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln, exendin-4/gastrin/xenin-8-Gln-Lys27-PAL or liraglutide/gastrin/xenin-8-Gln (each at 25 nmol/kg), where appropriate. (A-D) Insets depict 0-60 min AUC values. Values represent mean±S.E.M. for 8 mice. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to appropriate (A,B) glucose or (C,D) saline control. 

Figure 3. Effects of exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln and exendin-4(Lys27PAL)/gastrin/xenin-8-Gln on metabolic indices in ob/ob mice. (A-C,F) All factors were measured before and 31-days during (designated by bar) twice-daily treatment with saline vehicle (0.9% NaCl, i.p.), exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln or exendin-4(Lys27PAL)/gastrin/xenin-8-Gln (25 nmol/kg bw; i.p.) in ob/ob mice. Body fat mass on study day 31 is shown on inset of panel A. (D,E) 24 h glucose profile and HbA1c were measured on day 31, where arrows indicate timing of normal twice-daily injections in panel D. Values represent mean±S.E.M. for 8 mice. *p < 0.05, **p < 0.01 and ***p < 0.001 compared with saline treated ob/ob controls.

Figure 4. Effects of twice-daily administration of exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln and exendin-4(Lys27PAL)/gastrin/xenin-8-Gln on responses to glucose and GIP administration in ob/ob mice. Intraperitoneal (A,B) glucose tolerance and (C,D) GIP tolerance tests were conducted in ob/ob mice on day 31 after respective treatment regimens. Glucose and insulin were measured immediately before after injection of either (A,C) glucose (18 mmol/kg bw, i.p.) alone or (B,D) glucose in combination with GIP (25 nmol/kg bw; i.p.) in 18 h fasted ob/ob mice. (A-D) Overall AUC values for glucose and insulin are also presented. Values represent mean±S.E.M. for 8 mice. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to saline treated ob/ob controls.

Figure 5. Effects of twice-daily administration of exendin-4/gastrin, exendin-4/gastrin/xenin-8-Gln and exendin-4(Lys27PAL)/gastrin/xenin-8-Gln on insulin sensitivity, pancreatic insulin content, circulating glucagon and amylase activity in ob/ob mice. (A,B) Insulin (50 U/kg bw; i.p.) was injected at t=0 and glucose levels measured immediately before and 15, 30 and 60 min post-injection in non-fasted ob/ob mice following the respective treatment regimens. (B) Glucose AAC values for 0-60 min are depicted. (C) Pancreatic insulin content was measured by RIA following acid-ethanol pancreatic protein extraction. (D,E) Plasma glucagon and amylase activity were measured in terminal plasma samples. Values represent mean±S.E.M. for 8 mice. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to saline treated ob/ob controls.
Table 1. Amino acid sequence and percentage purity of peptides 
Peptide	Amino acid sequence	% purity
Exendin-4/gastrin	HGEGTFTSDLSKQMEEEAVRLFIEWLKN-AEEAc-AEEAc-YGWLDF-NH2	>95%





One letter amino acid sequence of peptides. AEEAc = 8-amino-3,6-dioxaoctanoic acid linker molecule; γ-Glu-PAL = γ-glutamyl-palmitate. 
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